Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis.

ABSTRACT:

Purpose of review

Development of hepcidin therapeutics has been a ground-breaking discovery in restoring iron homeostasis in several haematological disorders. The hepcidin mimetic, rusfertide, is in late-stage clinical development for treating polycythemia vera patients with a global phase 3 trial [NCT05210790] currently underway. Rusfertide serves as the first possible noncytoreductive therapeutic option to maintain haematocrit control and avoid phlebotomy in polycythemia vera patients. In this comprehensive review, we discuss the pathobiology of dysregulated iron metabolism in polycythemia vera, provide the rationale for targeting the hepcidin-ferroportin axis and elaborate on the preclinical and clinical trial evidence supporting the role of hepcidin mimetics in polycythemia ver

SUBMITTER: Handa S 

PROVIDER: S-EPMC9908837 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature